NVO — NOVO NORDISK A S
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 353278 ·
Last close
$37.91
Market Cap
$126.77B
52W High
$61.11
52W Low
$34.15
ADV30
13,073,661
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 78,488,000,000 | 61,388,000,000 | 27,061,000,000 | 20,989,000,000 | 594,941,000,000 | 44,482,000,000 | 373,664,000,000 |
| Mar 2026 | 96,823,000,000 | 83,225,000,000 | 59,618,000,000 | 48,557,000,000 | 559,221,000,000 | 21,127,000,000 | 356,156,000,000 |
| Dec 2025 | 79,144,000,000 | 63,996,000,000 | 31,736,000,000 | 26,891,000,000 | 542,902,000,000 | 26,464,000,000 | 348,855,000,000 |
| Sep 2025 | 74,976,000,000 | 57,072,000,000 | 23,682,000,000 | 20,006,000,000 | 512,288,000,000 | 32,084,000,000 | 342,392,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$131,881,000,000
Investing CF
$-83,537,000,000
Financing CF
$-22,242,000,000
CapEx
$-84,092,000,000
Dividends Paid
$-51,975,000,000
Buybacks
$-5,899,000,000
EPS Diluted TTM
$26.19
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$224,164,000,000
Inventory
$51,352,000,000
Receivables
$108,512,000,000
ST Investments
$500,000,000
EBIT TTM
$149,464,000,000
Pretax Income TTM
$148,749,000,000
Interest Exp TTM
$5,551,000,000
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$329,430,990,848
EBITDA
$173,677,002,752
Free Cash Flow
$37,673,250,816
Enterprise Value
$285,861,511,168
Total Cash
$44,982,001,664
Total Debt
$140,126,994,432
Shares Out
3,344,053,124
Trailing EPS
$4.09
Book Value
$7.74
ROE
59.8%
ROA
18.7%
Div Yield
4.17%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 309,064,000,000 | 127,658,000,000 | 102,434,000,000 | 542,902,000,000 | 348,855,000,000 | 194,047,000,000 | 119,102,000,000 |
| Dec 2024 | 290,403,000,000 | 128,339,000,000 | 100,988,000,000 | 465,630,000,000 | 322,144,000,000 | 143,486,000,000 | 120,968,000,000 |
| Dec 2023 | 232,261,000,000 | 102,574,000,000 | 83,683,000,000 | 314,486,000,000 | 207,925,000,000 | 106,561,000,000 | 108,908,000,000 |
| Dec 2022 | 176,954,000,000 | 74,809,000,000 | 55,525,000,000 | 241,257,000,000 | 157,771,000,000 | 83,486,000,000 | 78,887,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$3.40
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $40.00 · spot: $37.91 · call volume: 1,922 · put volume: 9,586
Expected Move to 2026-10-16:
±$1.97
(5.20%) —
implied range
$35.94 –
$39.88
· ATM straddle on $38.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BMY | BRISTOL MYERS SQUIBB CO | $127.47B | $62.40 | — |
| NONOF | NOVO NORDISK A S | $127.58B | $38.15 | — |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.51B | $522.81 | — |
| PFE | PFIZER INC | $162.55B | $28.52 | — |
| SNY | Sanofi | $98.79B | $41.23 | — |
News headlines (Yahoo Finance, 1h cache)
Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy
2026-09-30 23:30 · Yahoo
Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market?
2026-09-30 14:44 · Yahoo
If You Love Speculating, You Should Keep a Close Eye on Novo Nordisk Stock
2026-09-30 14:03 · Yahoo
Novo Nordisk Wegovy pill weight loss switch study results
2026-09-30 12:32 · Yahoo
Novo Nordisk (CPSE:NOVO B) Licensed A Once Weekly Oral GLP 1 GIP Drug
2026-09-29 19:05 · Yahoo
Novo Nordisk Delivers Fresh Challenge to Eli Lilly With Ozempic Data
2026-09-29 15:57 · Yahoo
Novo Goes Shopping in China for Its Next Obesity Pill
2026-09-29 14:20 · Yahoo
Eli Lilly stock rises on striking 23% weight loss in drug combo trial
2026-09-30 14:59 · Yahoo
Lilly Says Higher-Dose Zepbound Just Widened Its Lead Over Wegovy
2026-09-29 18:16 · Yahoo
Prediction: Eli Lilly’s Next Growth Wave Could Surprise Investors
2026-09-29 18:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.